

Effect of Ferric Carboxymaltose on Exercise Capacity in Patients With Iron Deficiency and Chronic Heart Failure (EFFECT-HF): A Randomized, Controlled Study

Purpose: To study the effects of treating iron deficiency (ID) in chronic heart failure patients with intravenous (iv) ferric carboxymaltose (FCM).

Trial Design: Prospective, randomized 1:1; controlled, open-label, international, multicenter, 2-arms; 172 stable, mild-moderate HF patients (NYHA II-III) with reduced exercise capacity were randomized (1:1) to either iv FCM or Standard of Care (SoC) for 24 weeks.

Primary Endpoint: peakVO₂ at 24 weeks

Trial Results

Conclusions: Peak VO₂ improved in patients who received FCM